Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide
0.1.0 - ci-build
Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide
0.1.0 - ci-build
Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide, published by Digital Health Agency (DHA), Kenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/nccpFHIRIG/ and changes regularly. See the Directory of published versions
| Active as of 2026-06-04 |
{
"resourceType" : "CodeSystem",
"id" : "med-clinical-category-cs",
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem med-clinical-category-cs</b></p><a name=\"med-clinical-category-cs\"> </a><a name=\"hcmed-clinical-category-cs\"> </a><p>This case-sensitive code system <code>https://nshr-uat.sha.go.ke/fhir/CodeSystem/med-clinical-category-cs</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">CHEMOTHERAPY<a name=\"med-clinical-category-cs-CHEMOTHERAPY\"> </a></td><td>Chemotherapy</td><td>Cytotoxic agent used to kill or inhibit cancer cells.</td></tr><tr><td style=\"white-space:nowrap\">IMMUNOTHERAPY<a name=\"med-clinical-category-cs-IMMUNOTHERAPY\"> </a></td><td>Immunotherapy</td><td>Agent that stimulates the immune system against cancer.</td></tr><tr><td style=\"white-space:nowrap\">TARGETED-THERAPY<a name=\"med-clinical-category-cs-TARGETED-THERAPY\"> </a></td><td>Targeted Therapy</td><td>Agent targeting specific molecular markers on cancer cells.</td></tr><tr><td style=\"white-space:nowrap\">HORMONAL-THERAPY<a name=\"med-clinical-category-cs-HORMONAL-THERAPY\"> </a></td><td>Hormonal Therapy</td><td>Agent that blocks or modifies hormone-driven tumour growth.</td></tr><tr><td style=\"white-space:nowrap\">SUPPORTIVE-CARE<a name=\"med-clinical-category-cs-SUPPORTIVE-CARE\"> </a></td><td>Supportive Care</td><td>Medication to manage side effects or improve tolerability.</td></tr><tr><td style=\"white-space:nowrap\">ANTI-EMETIC<a name=\"med-clinical-category-cs-ANTI-EMETIC\"> </a></td><td>Anti-emetic</td><td>Agent to prevent or treat nausea and vomiting.</td></tr><tr><td style=\"white-space:nowrap\">GROWTH-FACTOR<a name=\"med-clinical-category-cs-GROWTH-FACTOR\"> </a></td><td>Growth Factor</td><td>Colony-stimulating factor to support blood cell recovery.</td></tr><tr><td style=\"white-space:nowrap\">CORTICOSTEROID<a name=\"med-clinical-category-cs-CORTICOSTEROID\"> </a></td><td>Corticosteroid</td><td>Steroid given as part of or to support the oncology regimen.</td></tr><tr><td style=\"white-space:nowrap\">BISPHOSPHONATE<a name=\"med-clinical-category-cs-BISPHOSPHONATE\"> </a></td><td>Bisphosphonate</td><td>Agent for prevention or treatment of bone metastasis.</td></tr><tr><td style=\"white-space:nowrap\">ANALGESIC<a name=\"med-clinical-category-cs-ANALGESIC\"> </a></td><td>Analgesic</td><td>Pain management medication in the cancer care context.</td></tr></table></div>"
},
"url" : "https://nshr-uat.sha.go.ke/fhir/CodeSystem/med-clinical-category-cs",
"version" : "0.1.0",
"name" : "MedClinicalCategoryCS",
"title" : "Kenya Medication Clinical Category Code System",
"status" : "active",
"experimental" : false,
"date" : "2026-06-04T14:49:30+00:00",
"publisher" : "Digital Health Agency (DHA), Kenya",
"contact" : [
{
"name" : "Digital Health Agency (DHA), Kenya",
"telecom" : [
{
"system" : "url",
"value" : "https://dha.go.ke"
},
{
"system" : "email",
"value" : "info@dha.go.ke"
}
]
},
{
"name" : "Digital Health Agency Kenya – FHIR Team",
"telecom" : [
{
"system" : "email",
"value" : "info@dha.go.ke",
"use" : "work"
},
{
"system" : "url",
"value" : "https://dha.go.ke",
"use" : "work"
}
]
}
],
"description" : "Codes classifying the clinical role of a medication within an oncology regimen.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "KE",
"display" : "Kenya"
}
]
}
],
"caseSensitive" : true,
"content" : "complete",
"count" : 10,
"concept" : [
{
"code" : "CHEMOTHERAPY",
"display" : "Chemotherapy",
"definition" : "Cytotoxic agent used to kill or inhibit cancer cells."
},
{
"code" : "IMMUNOTHERAPY",
"display" : "Immunotherapy",
"definition" : "Agent that stimulates the immune system against cancer."
},
{
"code" : "TARGETED-THERAPY",
"display" : "Targeted Therapy",
"definition" : "Agent targeting specific molecular markers on cancer cells."
},
{
"code" : "HORMONAL-THERAPY",
"display" : "Hormonal Therapy",
"definition" : "Agent that blocks or modifies hormone-driven tumour growth."
},
{
"code" : "SUPPORTIVE-CARE",
"display" : "Supportive Care",
"definition" : "Medication to manage side effects or improve tolerability."
},
{
"code" : "ANTI-EMETIC",
"display" : "Anti-emetic",
"definition" : "Agent to prevent or treat nausea and vomiting."
},
{
"code" : "GROWTH-FACTOR",
"display" : "Growth Factor",
"definition" : "Colony-stimulating factor to support blood cell recovery."
},
{
"code" : "CORTICOSTEROID",
"display" : "Corticosteroid",
"definition" : "Steroid given as part of or to support the oncology regimen."
},
{
"code" : "BISPHOSPHONATE",
"display" : "Bisphosphonate",
"definition" : "Agent for prevention or treatment of bone metastasis."
},
{
"code" : "ANALGESIC",
"display" : "Analgesic",
"definition" : "Pain management medication in the cancer care context."
}
]
}